Teva Pharmaceutical Industries Limited (TLV:TEVA)
Market Cap | 71.66B |
Revenue (ttm) | 56.02B |
Net Income (ttm) | -528.98M |
Shares Out | n/a |
EPS (ttm) | -0.47 |
PE Ratio | n/a |
Forward PE | 7.37 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 767,277 |
Average Volume | 1,368,080 |
Open | 6,300.00 |
Previous Close | 6,325.00 |
Day's Range | 6,257.00 - 6,310.00 |
52-Week Range | 4,865.00 - 8,431.00 |
Beta | 0.71 |
RSI | 46.21 |
Earnings Date | Nov 5, 2025 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe
(RTTNews) - Formycon AG (FYB.F), Bioeq AG and Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday announced the launch of FYB201/Ranivisio or ranibizumab in Europe as the first Lucentis biosimilar a...
Teva (TEVA) Partners with Prestige Biopharma for Tuznue in Europe
Teva (TEVA) Partners with Prestige Biopharma for Tuznue in Europe

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received European Commission (EC) market...

Teva Vs. Viatris: Who Will Dominate In President Trump's America?
Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA...

AFI Development
Teva Pharmaceutical Industries Astellas Pharma 3000 . AFI Flex . , . , Teva 305 ( 1840 .) , Astellas 150 ( 1000 .) . AFI Development, , . Teva, Astellas.
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Administration has...
FDA Expands Use of Teva's (TEVA) Uzedy for Bipolar I Disorder
FDA Expands Use of Teva's (TEVA) Uzedy for Bipolar I Disorder
Teva long-acting antipsychotic Uzedy gains indication for bipolar disorder
FDA Approves Teva's (TEVA) Uzedy for Bipolar I Disorder Maintenance
FDA Approves Teva's (TEVA) Uzedy for Bipolar I Disorder Maintenance

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...
IDEV, SPOT, TEVA, AER: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) w...
Harel Insurance Investments & Financial Services Ltd. ...
Harel Insurance Investments & Financial Services Ltd. Increases Stake in Teva Pharmaceutical Industries Ltd.

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration is reportedly planning to exclude imported generic drugs from tariffs. White House spokesman Kush Desai told the Wall Street Journal that "the administration is not actively d...

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside
Teva Pharmaceutical Industries is regaining investor interest as restructuring efforts drive margin improvements. Read why TEVA stock is a Buy.
FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors
FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors
JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News
JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News
Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus
Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus (NYSE: TEVA). And retail traders should know. We noticed this today when the trades showed up on public...
Notable ETF Inflow Detected - IXUS, PDD, NU, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI Total International Stock ETF (Symbol: IXUS) where w...

Teva Releases Q3 2025 Aide Memoire
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its...

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial re...

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors
Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment ma...
November 7th Options Now Available For Teva Pharmaceutical Industries (TEVA)
Investors in Teva Pharmaceutical Industries Ltd (Symbol: TEVA) saw new options begin trading today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News
TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News
Is Teva Pharmaceutical Indus Gaining or Losing Market Support?
Teva Pharmaceutical Indus's (NYSE: TEVA) short interest as a percent of float has risen 9.14% since its last report. According to exchange reported data, there are now 50.51 million shares sold short...